ArticleItalian journal of pediatrics2025
How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation.
Article in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this Debate, based on our clinical data from the "pre-nirsevimab" and "first year of nirsevimab implementation" bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible newborns and infants during the 2024-25 season in Italy. MAIN BODY: Starting with a pre-nirsevimab prospective cohort of 780 newborns, we documented that 84 (9.2%) were diagnosed with acute bronchiolitis (45 of them (5.8% of the cohort) were RSV positive. 44 patients (5.6%) were hospitalized due to bronchiolitis, of which 7 (0.9%) patients were admitted to the Pediatric Intensive Care Unit. Among hospitalized, 31 infants (70%) had RSV infection. Secondly, we evaluated the impact on bronchiolitis admissions during the first year of nirsevimab use in our region, showing a negligible effect on the most severe cases, probably due to the fact that a low coverage will risk to miss the relatively small number of infants (about 10%) that will develop RSV bronchiolitis in the first year of life. These findings inspired our clinical insights and reflections arguing that without a long-term, cost-conscious approach to implementation, even major scientific breakthroughs like nirsevimab risk becoming public health failures.
conclusionsOur clinical insights and reflections aim to inspire deeper engagement among policymakers, health agencies, and clinicians to better adapt and integrate RSV preventive strategies-maximizing benefit not only for susceptible infants, but for society at large. In a world of finite healthcare resources, optimizing both the reach and the value of such essential interventions is imperative, given the multitude and diversity of health needs our society is facing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.